No Surprises Please: Australian Pharma Tells Govt Ahead Of Budget
As the Australian government prepares its 2019-2020 federal budget, the pharmaceutical industry is calling for business certainty and warns against the introduction of any surprise measures under the Pharmaceutical Benefits Scheme.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.